PGEN Earnings – Q3 2026

Precigen, Inc. (Nasdaq: PGEN) reported third-quarter results on November 4, 2026, with total revenue of $74.1 million driven by strong sequential growth in PAPZIMEOS net product sales of $72.9 million (up 37% quarter-over-quarter).

The company achieved profitability for the second consecutive quarter, generated positive operating cash flow a full quarter ahead of prior guidance, and continued to expand commercial adoption of its FDA-approved therapy for recurrent respiratory papillomatosis (RRP).

Actual Results: Commercial Momentum and Early Profitability

• Total revenue reached $74.1 million, with PAPZIMEOS contributing $72.9 million, up 37% sequentially from the second quarter and bringing launch-to-date net product revenue to approximately $151 million.
• GAAP diluted EPS was $0.08, ahead of consensus expectations of roughly $0.06.
• Net income was $35.8 million for the quarter (and $47.9 million for the nine months), a sharp improvement from the large loss in the prior-year period.
• The company generated $11.9 million in positive operating cash flow, achieving this milestone a full quarter earlier than previously guided.
• Cash, cash equivalents, and investments rose to $51.0 million from $38.7 million at the end of the second quarter, supported by strong product uptake and collections.
• More than 500 patients had initiated PAPZIMEOS treatment.
• Broad commercial coverage spanning over 315 million U.S. lives — vast majority of insured Americans now have a covered pathway to receive it if their doctor prescribes it.

Why It Matters: From Launch to Self-Funding Trajectory

• The continued sequential growth in PAPZIMEOS revenue demonstrates sustained commercial traction for the first-line RRP therapy and validates the company’s commercial execution.
• Achieving profitability and positive operating cash flow ahead of guidance marks a critical inflection, reducing near-term financing risk and supporting further investment in the franchise.
• The rising cash balance and substantial receivables provide liquidity flexibility as the company scales manufacturing and commercial infrastructure.
• Early commercial success positions Precigen to capture a meaningful share of the RRP market, though emerging competition will test durability of the ramp.

What’s Ahead

• Management highlighted ongoing patient uptake, treatment-site activation, and hub registrations as supporting continued revenue growth.
• The company received FDA Platform Technology Designation for its AdenoVerse platform, which may accelerate development of additional therapies. Long-term follow-up data continue to show durable complete responses.
• While no formal fourth-quarter or full-year revenue guidance was provided, commentary indicated confidence in further adoption.
• A competing RRP therapy is approaching the market, which management has factored into planning.

AdenoVerse

AdenoVerse is Precigen’s proprietary immunotherapeutic platform. It uses a library of engineered adenoviral vectors (including gorilla adenovectors) to deliver antigens, immunomodulators, and therapeutic genes that train the immune system to recognize and attack specific targets.

Key advantages include:

• Large genetic payload capacity (up to ~12 kb), allowing multiple genes to be expressed in a controlled way.
• Low seroprevalence in humans, which reduces the chance that pre-existing antibodies neutralize the vector.
• Suitability for repeat dosing, enabling boosted immune responses over time.
• Non-replicating design, which supports a favorable safety profile.
• Scalable manufacturing processes.

PAPZIMEOS (formerly PRGN-2012), Precigen’s approved therapy for recurrent respiratory papillomatosis, is the first commercial product built on AdenoVerse. The company is also advancing other candidates, such as PRGN-2009 for HPV-associated cancers, on the same platform.

In September 2026, the FDA granted AdenoVerse Platform Technology Designation. This recognition can help streamline development of future therapies by allowing Precigen to leverage manufacturing and preclinical data from PAPZIMEOS, potentially reducing duplication of work and enabling earlier FDA engagement.

Risks to Forward Expectations

• Sequential growth in PAPZIMEOS moderated from the prior quarter’s pace, and further deceleration is possible as the patient base expands.
• Entry of a competitor in the RRP market could pressure share, pricing, or uptake.
• The company remains early in its commercial lifecycle, with revenue still concentrated in a single product.
• Execution risk exists around scaling manufacturing, maintaining reimbursement access, and converting the growing patient pipeline into sustained revenue.

Bottom Line: Commercial Inflection with Positive Cash Flow Ahead of Plan

Precigen delivered a solid commercial quarter, with PAPZIMEOS revenue continuing to scale and the company reaching both profitability and positive operating cash flow earlier than guided. The combination of expanding patient adoption, a strengthening balance sheetA financial "snapshot" that reveals exactly what a company owns and owes at a specific moment in time. It follows the fundamental formula: Assets = Liabilities + Equity. By subtracting what is owed (liabilities) from what is owned (assets), the balance sheet shows the "book value" or the net worth belonging to the owners. More, and platform validation supports the transition from a development-stage story to a commercial biopharma company.

While competition and the pace of further uptake remain key variables, the results underscore that PAPZIMEOS has established meaningful early traction as a standard-of-care option for adults with RRP. Sustained execution on commercial growth and disciplined spending will determine how quickly the company can build durable, multi-year cash flow from the franchise.